Nordea upgrades AstraZeneca to buy, doubles rating after analyst change

Nordea raised its recommendation on AstraZeneca from sell to buy, a two-notch upgrade following an analyst change. The move reflects a shift in sentiment toward the pharma stock, though the underlying rationale is not detailed. This is a single-broker action, not a broad market signal.